

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): ANDERSON, D. et al Attorney Docket No:
Serial No: 07/978,891 Group Art Unit: 1805
Filed: 13 November 1992 Examiner:
Title: THERAPEUTIC APPLICATION OF
CHIMERIC ANTIBODY TO HUMAN
B LYMPHOCYTE RESTRICTED
DIFFERENTIATION ANTIGEN
FOR TREATMENT OF B CELL LYMPHOMA

GP 1805
1805
Accepted
94 JAN -3 PM 1:46
RECEIVED
GROUP 180


Express Abandonment of Patent Application Under 37 CFR 1.138

HONORABLE COMMISSIONER OF PATENTS
AND TRADEMARKS
BOX NON FEE AMENDMENT
WASHINGTON, D.C. 20231

Applicants hereby expressly, and without prejudice, abandon the above-identified patent application, BUT NOT THE INVENTION AS DISCLOSED AND CLAIMED. A Continuation-In-Part application based upon this application was filed on November 3, 1993, and has been assigned Serial Number 08/149, 099. Therefore, in an effort to focus attention and resources on the CIP, Applicants have opted to abandon the present application in favor of the CIP. Applicants further note that an Official Action issued in this case on June 15, 1992; a response thereto will not be filed. Such non-response is not to be interpreted as an admission, either express or implied, that Applicants accept any of the points set forth by the Office in the Official Action.


Respectfully submitted,

December 15 , 1993


Richard P. Burgoon, Jr.,
Intellectual Property Counsel
Reg. No. 34,787
IDEC Pharmaceuticals Corporation
11011 Torreyana Road
San Diego, CA 92121
619-550-8680

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Box Non-Fee Amendment, Washington, D.C. 20231, on December 15, 1993.

Date: December 15, 1993


Richard P. Burgoon, Jr.